New treatments in development for Pseudomonas aeruginosa infections in the lungs of individuals with cystic fibrosis
Open Access
- 1 October 2014
- journal article
- review article
- Published by Taylor & Francis in Orphan Drugs: Research and Reviews
- Vol. 4, 71-81
Abstract
In 1989, with the discovery of the genetic mutation causing cystic fibrosis (CF), a cure for this terrible disease seemed just around the corner. Though significant progress has been made to improve the quality of life of CF patients, a remedy for CF is yet to be found. Of great concern, such bacteria as Pseudomonas aeruginosa establish chronic infections that are extremely difficult to eradicate. P. aeruginosa thrives in the CF lung environment, where it protects itself from the host inflammatory defense and contributes immensely to the lung inflammation and tissue destruction seen with the disease. Tackling and eradicating P. aeruginosa infection in the CF lung holds the key to lessen the suffering of these individuals. Unfortunately, current antibiotic regimens are insufficient to eliminate P. aeruginosa from the CF lung. In this review, we address recent drugs that are currently under development to eradicate P. aeruginosa infection in the airways of patients with CF. We discuss the P. aeruginosa infection from the perspective of CF, the shortcomings of current drugs, and the upcoming drugs that are under clinical trials and development. These new drugs and therapies hold much promise for treating recalcitrant P. aeruginosa infections and improving the lives of individuals with CF.Keywords
This publication has 67 references indexed in Scilit:
- Pharmacological treatment of the basic defect in cystic fibrosisCell Biology International, 2014
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative BacilliDrugs, 2013
- Influence of clove oil on certain quorum-sensing-regulated functions and biofilm of Pseudomonas aeruginosa and Aeromonas hydrophilaJournal of Biosciences, 2013
- Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A Phase I, Randomized, Dose-Escalation StudyClinical Therapeutics, 2013
- Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infectionPediatric Pulmonology, 2013
- Antibiofilm and quorum sensing inhibitory potential of Cuminum cyminum and its secondary metabolite methyl eugenol against Gram negative bacterial pathogensFood Research International, 2012
- Inhibitors of the Pseudomonas aeruginosa quorum‐sensing regulator, QscRBiotechnology and Bioengineering, 2010
- CFTR: More than just a chloride channelPediatric Pulmonology, 2005
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- Seizure Propensity With ImipenemArchives of internal medicine (1960), 1990